Real World Evidence in Drug Development
Chris Chinn -Sanofi
Acceptability of real world evidence
R-D decision anticipate the HTA decision
phase 3b supplement
Would we accept the uncertain for a period of time while waiting for the study to complete?
to what extend generate the study plan generate data for effectiveness?
the concern of pharma/producer of health technology : will the study be accepted by regulators and HTA agencies?
IMI Get real Work Packages
understading the efficacy-effectiveness gap
clinical design barriers
best practices-predictive models
Questions asked at workshop of Pragmatic Design of Clinical Trials
Get Real deliverables